Zentalis Pharmaceuticals (ZNTL) Stock: Buy, Sell, or Hold?
ZNTL - Zentalis Pharmaceuticals, Inc. Common Stock
$1.96
-0.03 (-1.51%)
▼
5d:
-11.31%
30d:
-24.76%
90d:
-57.85%
WAIT
LOW Confidence
Analysis Updated: Oct 30, 2026 12:00 AM ET
Earnings: Nov 09, 2026
7d
Get Alerted When ZNTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ZNTL is down 11.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ZNTL is down 11.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ZNTL is currently trading at $1.96, which is considered oversold relative to its 30-day fair value range of $2.16 to $2.77.
Technical Outlook: Technically, ZNTL is in a strong downtrend. Immediate support is located at $1.86, while resistance sits at $2.47.
Market Sentiment: ZNTL scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.44 (+279.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZNTL is in a strong downtrend. Immediate support is located at $1.86, while resistance sits at $2.47.
Market Sentiment: ZNTL scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.44 (+279.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.16 -
$2.77
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 279.8% below Wall St target ($7.44)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.16 -
$2.77
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.86
Resistance Level
$2.47
Current Trend
Strong Downtrend
Technical data as of
Oct 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.11
Wall Street Target
$7.44
(+279.8%)
Share & Embed Analysis
Last updated: November 01, 2026 4:08 AM ET
Data refreshes hourly during market hours. Next update: 5:08 AM
Data refreshes hourly during market hours. Next update: 5:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZNTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1144 | 51 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 65 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 41 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 54 HOLD |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$117 | 66 BUY |
